| Outcome Measures: |
Primary: Part 1: Number of treatment emergent adverse events, Number of events, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6)|Part 2: Number of treatment emergent adverse events, Number of events, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14) | Secondary: Number of hypoglycaemic episodes of alert value (level 1) below 3.9 mmol/L (70 mg/dL) and equal to or above 3.0 mmol/L (54 mg/dL), Number of episodes, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6)|Number of hypoglycaemic episodes of alert value (level 1) below 3.9 mmol/L (70 mg/dL) and equal to or above 3.0 mmol/L (54 mg/dL), Number of episodes, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14)|Number of clinically significant hypoglycaemic episodes (level 2) below 3.0 mmol/L (54 mg/dL), Number of episodes, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6)|Number of clinically significant hypoglycaemic episodes (level 2) below 3.0 mmol/L (54 mg/dL), Number of episodes, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14)|Number of severe hypoglycaemic episodes (level 3), Number of episodes, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 15, visit 6)|Number of severe hypoglycaemic episodes (level 3), Number of episodes, From IMP administration at day 1 (visit 2) until completion of post-treatment end-of-trial visit (day 30, visit 14)|Area under the serum NNC0472-0147 concentration-time curve after a single dose, pmol\*h/L, From 0 hours until infinity after a single IMP administration at day 1 (visit 2).|Maximum observed serum NNC0472-0147 concentration after a single dose, pmol/L, From 0 hours until last measurement time after a single IMP administration at day 1 (visit 2)|Area under the serum NNC0472-0147 concentration-time curve during one dosing interval at steady state, pmol\*h/L, From 0 to 24 hours after last multiple IMP administration at day 14 (visit 9)|Maximum observed serum NNC0472-0147 concentration at steady state, pmol/L, From 0 to 24 hours after last multiple IMP administration at day 14 (visit 9)
|
